ArticleSynthetic and systems biotechnology2021
Rationally optimized generation of integrated
Article in Synthetic and systems biotechnology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 38 citations in OpenAlex.
- Metabolic engineering of endogenous MEP pathway for enhanced lycopene production inSynthetic and systems biotechnology · 2026Article
- The Mevalonate Pathway: Innovations, Applications, and Challenges in Biotechnology with Emphasis on Fungal Biology.Journal of fungi (Basel, Switzerland) · 2026Review
- Strategies for Metabolic Engineering ofMolecules (Basel, Switzerland) · 2026Review
- Unveiling Metabolic Engineering Strategies by Quantitative Heterologous Pathway Design.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024Article
- Stable Platform for Mevalonate Bioproduction from COACS sustainable chemistry & engineering · 2024Article
- Article
- Recent advances in lycopene and germacrene a biosynthesis and their role as antineoplastic drugs.World journal of microbiology & biotechnology · 2024Review
- Application of Acetate as a Substrate for the Production of Value-Added Chemicals inMicroorganisms · 2024Review
- Rational engineering ofFrontiers in microbiology · 2024Article
- Bioengineering of the Marine DiatomInternational journal of molecular sciences · 2023Article
- High-yield production of protopanaxadiol from sugarcane molasses by metabolically engineered Saccharomyces cerevisiae.Microbial cell factories · 2022Article
- Engineering plant family TPS into cyanobacterial host for terpenoids production.Plant cell reports · 2022Review
- Construction of an Escherichia coli cell factory to synthesize taxadien-5α-ol, the key precursor of anti-cancer drug paclitaxel.Bioresources and bioprocessing · 2022Article
- Bioproduction of Linalool From Paper Mill Waste.Frontiers in bioengineering and biotechnology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The stability and high productivity of heterogeneous terpenoid production in
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.